Fertility Preservation in Oncology and Social Contex... | MDster You are offline Back online! [ ](/) Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) Menu Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) [ Login ](https://mdster.com/auth/login) 1. [ Home ](https://mdster.com) 2. [ Blog ](https://mdster.com/blog) 3. [ Medical Education ](https://mdster.com/blog?category=medical-education) 4. Fertility Preservation in Oncology and Social Contexts: Oncofertility, Minors, and Ovarian Tissue Cryopreservation [ Medical Education ](https://mdster.com/blog?category=medical-education) Fertility Preservation in Oncology and Social Contexts: Oncofertility, Minors, and Ovarian Tissue Cryopreservation ==================================================================================================================== A breakroom-level, board-focused approach to urgent referrals, consent/assent in kids, and the “don’t forget OTC exists” option. [ MDster Editorial Team ](https://mdster.com/about) · Mar 02, 2026 · 7 min read · 96 [ Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) | [Corrections Policy](https://mdster.com/corrections) [ Obstetrics & Gynecology ](https://mdster.com/blog?tag=obstetrics-gynecology) [ Oncofertility ](https://mdster.com/blog?tag=oncofertility) [ Reproductive Ethics ](https://mdster.com/blog?tag=reproductive-ethics) [ Fertility Preservation ](https://mdster.com/blog?tag=fertility-preservation) [ Reproductive Endocrinology ](https://mdster.com/blog?tag=reproductive-endocrinology) [ OBGYN Boards ](https://mdster.com/blog?tag=obgyn-boards) Share this article Share this post A 26-year-old with newly diagnosed lymphoma is told chemo starts “next week.” She asks, almost as an afterthought, “Will I still be able to have kids?” If your answer is anything other than “Yes—we’re calling REI today,” you’re already behind. Fertility preservation (FP) lives at the intersection of time pressure, informed consent, and future autonomy. In March 2026 practice, the expectations are clear: **counsel early, refer urgently, document well, and don’t gatekeep based on your assumptions about prognosis, parity, or relationship status.** The mental model: two clocks and one conversation ------------------------------------------------- In oncofertility, you’re managing: 1. **The cancer clock** (how quickly gonadotoxic therapy must start) 2. **The gonadal clock** (baseline ovarian reserve, age, and how treatment will accelerate follicle loss) Your job is not to predict whether the patient will “really want kids later.” Your job is to **protect options** while respecting patient values and the oncology plan. On boards, the classic pitfall is treating FP like a “nice-to-have” consult. It’s not. It’s part of standard counseling for patients facing therapies that threaten reproductive function. Oncofertility urgency pathways: what “fast-track” should look like ------------------------------------------------------------------ When people miss FP, it’s usually not because no options existed—it’s because the system moved too slowly. Build (or demand) a fast-track pathway. **What I want you to do, operationally:** - **At diagnosis (same day if possible):** identify reproductive potential, flag gonadotoxic risk, and ask about future family-building (including “unsure”). - **Refer immediately** to an FP-capable REI team; don’t wait for “oncology clearance” as a pretext to delay. - **Coordinate, don’t compete:** REI should talk directly with oncology about timing, central lines, anticoagulation, neutropenia risk, and whether a 10–14 day window exists. ### Choosing an FP strategy by time available Here’s the practical triage table I teach residents: Time before gonadotoxic therapyBest-established FP optionsOBGYN exam-relevant notes**~2 weeks****Oocyte or embryo cryopreservation** with random-start stimulation**Random-start** protocols avoid waiting for menses; ER+ breast cancer often uses **letrozole/tamoxifen co-treatment** during stimulation.**Days (can’t delay)****Ovarian tissue cryopreservation (OTC)** (selected patients)OTC is **no longer “experimental”** in current guidance; key for **prepubertal** patients and true urgency.**Pelvic radiation planned****Ovarian transposition** (± cryopreservation)Know it’s a surgical option to reduce radiation dose to ovaries; uterine radiation still threatens pregnancy.**Adjunct only****GnRH agonist ovarian suppression** during chemo (selected settings)Boards love this trap: it’s **not a substitute** for cryopreservation when time/eligibility allows. > **Clinical Pearl:** If the oncologist says, “We can’t delay chemo,” your next sentence should be, “Understood—then we need to discuss **OTC and/or ovarian transposition** today, not next week.” Ethical issues in minors: don’t confuse parental permission with patient assent ------------------------------------------------------------------------------- FP in children and adolescents is ethically loaded because you’re acting on **future interests** with **present-day burdens**. ### The ethical spine - **Parents/guardians provide permission**, but when the child can understand in an age-appropriate way, you should seek **assent**. - Aim to preserve the child’s **“open future”** without coercion. - Be explicit about **what is established vs investigational**, especially in prepubertal patients. ### Common real-world friction points (and how to handle them) - **The teen who doesn’t want parents involved:** know your local laws, but ethically you still should maximize the adolescent’s voice, privacy, and voluntary agreement. - **The parent who wants everything done, regardless of risk:** bring the discussion back to proportionality—surgical risk, treatment delay, and realistic likelihood of later use. - **The “future ownership” problem:** cryopreserved tissue/gametes will outlive childhood. Plan for what happens at the age of majority (re-consent), and document disposition preferences where your institution allows. Board-style pitfall: assuming “minors can’t consent so we skip FP.” Wrong. The ethical standard is **best interest + assent when possible**, not avoidance. Ovarian tissue cryopreservation (OTC): the awareness concept you need on rounds ------------------------------------------------------------------------------- OTC is the option people forget—until it’s the only one left. ### What it is (conceptually) A surgeon removes ovarian cortical tissue (usually laparoscopically), which contains **thousands of primordial follicles**, and the tissue is cryopreserved. Later, tissue can be **reimplanted (usually orthotopically)** to restore ovarian function and enable conception (often spontaneous, sometimes with ART). ### Who it’s for Think of OTC when: - **Prepubertal girls** need gonadotoxic therapy (no mature oocyte retrieval pathway) - **Treatment cannot be delayed** long enough for ovarian stimulation and retrieval - **High gonadotoxic risk** is expected and the patient wants biologic options ### The safety asterisk: malignant contamination This is where grown-up counseling matters. **Reimplantation can theoretically reseed malignancy**, and the risk varies by cancer type. - Hematologic malignancies (especially leukemia) raise the biggest concern for ovarian involvement. - “Screening” tissue is imperfect; you’re balancing fertility potential against oncologic safety. On boards, expect a question that’s really about **indications and limitations**, not surgical technique: OTC is established, useful in urgency/prepuberty, but requires **oncology collaboration** and careful selection. Social fertility preservation: ethically permissible—if you counsel honestly ---------------------------------------------------------------------------- “Social” (planned) oocyte cryopreservation is now common: patients freezing eggs to hedge against **age-related fertility decline**, unstable partnership status, career timing, or caregiving realities. Ethically, it’s generally permissible—but the ethical failure happens when clinicians (or clinics) oversell it. ### How to counsel without selling false certainty - **Be blunt about age:** outcomes track strongly with **age at freezing** and oocyte yield. - **Don’t promise a baby:** cryopreservation reduces risk; it doesn’t erase biology. - **Name the hidden commitments:** storage fees, future IVF costs, and the emotional weight of disposition decisions. - **Discuss embryo vs oocyte freezing** when a partner exists, including legal/ethical issues if relationships change. Equity matters here. Social FP is often accessed by the resourced; oncofertility is time-critical and medically driven. Don’t let that distinction bias your urgency or empathy. Clinical correlations: what shows up in OBGYN practice (and exams) ------------------------------------------------------------------ - **Breast cancer (ER+):** ovarian stimulation can be done with **estrogen-modulating co-treatment** (often letrozole-based protocols). Don’t reflexively deny FP because “estrogen will feed the tumor”—coordinate with oncology and REI. - **Cervical cancer needing pelvic RT:** remember **ovarian transposition** (and counsel that uterine radiation can still compromise pregnancy; gestational carrier may be needed). - **Adolescents:** prioritize assent, minimize coercion, and distinguish **established options** (e.g., sperm cryo postpuberty; OTC for selected patients) from **investigational** ones (notably prepubertal testicular tissue cryopreservation). Key Takeaways ------------- - **Treat FP counseling as standard of care** for patients facing gonadotoxic therapy—discuss it early and document it. - **Use a time-based triage:** ~2 weeks allows oocyte/embryo cryo (often random-start); true urgency pushes you to **OTC** considerations. - **In minors:** seek **assent** when developmentally possible; protect future autonomy; clarify what’s established vs investigational. - **OTC is no longer considered experimental** in contemporary guidance, but selection is key due to surgical risks and potential malignant contamination. - **Planned (social) oocyte cryopreservation is ethically permissible**, but only with realistic counseling about age, success rates, costs, and future decision points. Conclusion ---------- Fertility preservation is one of the rare moments where a single phone call can change the arc of a survivor’s life. Move fast, counsel straight, involve minors ethically, and keep OTC in your mental toolbox for the patient who doesn’t have time to wait for a follicular phase. References (4) ------------------ 1. 1. [ www.asrm.org/practice-guidance/practice-committee-documents/fertility-preservation-in-patients-with-medical-indications-a-committee-opinion-2026 ](https://www.asrm.org/practice-guidance/practice-committee-documents/fertility-preservation-in-patients-with-medical-indications-a-committee-opinion-2026/) 2. 2. [ pubmed.ncbi.nlm.nih.gov/40106739 ](https://pubmed.ncbi.nlm.nih.gov/40106739/) 3. 3. [ www.asrm.org/practice-guidance/ethics-opinions/planned-oocyte-cryopreservation ](https://www.asrm.org/practice-guidance/ethics-opinions/planned-oocyte-cryopreservation/) 4. 4. [ pubmed.ncbi.nlm.nih.gov/32071259 ](https://pubmed.ncbi.nlm.nih.gov/32071259/) Keep going Build confidence in OB/GYN with focused practice -------------------------------------------------- - Labor & delivery + postpartum essentials - Gynecology, screening, and common procedures - Review weak topics and improve faster [ Start practicing ](https://mdster.com/user/dashboard) [ Explore Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features) No credit card required. Full access to all features. No commitment. Cancel anytime. [ Back to all posts ](https://mdster.com/blog) Discussion () ----------------- Join the discussion [ Log in ](https://mdster.com/auth/login) or [ Sign up ](https://mdster.com/auth/register) No comments yet Be the first to share your thoughts! ![]() Related Posts ------------- [ ![Anxiety, Depression, and Breathlessness in Severe COPD/Asthma Overlap](https://mdster.com/storage/blog/images/anxiety-depression-and-breathlessness-in-severe-copdasthma-overlap.jpg) Medical Education ### Anxiety, Depression, and Breathlessness in Severe COPD/Asthma Overlap A focused Family Medicine review of anxiety, depression, and dyspnea in severe COPD/asthma overlap, with safer prescribing, breathing retraining, and board-style pitfalls. 6 min read 0 comments ](https://mdster.com/blog/anxiety-depression-and-breathlessness-in-severe-copdasthma-overlap) [ ![IBS Subtypes and Diagnosis: Rome IV, IBS-C/D, and Colonoscopy](https://mdster.com/storage/blog/images/ibs-subtypes-and-diagnosis-rome-iv-ibs-cd-and-colonoscopy.jpg) Medical Education ### IBS Subtypes and Diagnosis: Rome IV, IBS-C/D, and Colonoscopy A focused Internal Medicine review of IBS diagnosis: how to use Rome IV concepts, separate IBS-C from IBS-D and mixed IBS, and decide when colonoscopy is truly indicated. 7 min read 0 comments ](https://mdster.com/blog/ibs-subtypes-and-diagnosis-rome-iv-ibs-cd-and-colonoscopy) [ ![Congenital Hypothyroidism: Screening, Levothyroxine, Outcomes](https://mdster.com/storage/blog/images/congenital-hypothyroidism-screening-levothyroxine-outcomes.jpg) Medical Education ### Congenital Hypothyroidism: Screening, Levothyroxine, Outcomes High-yield review of congenital hypothyroidism for Pediatrics trainees, covering newborn screening pitfalls, urgent levothyroxine treatment, and developmental follow-up. 6 min read 0 comments ](https://mdster.com/blog/congenital-hypothyroidism-screening-levothyroxine-outcomes) [ ](/) Master your medical exams with evidence-based learning. [ GET IT ON Google Play ](https://play.google.com/store/apps/details?id=com.mdster.app) ### Platform - [Home](https://mdster.com) - [Features](https://mdster.com/features) - [Pricing](https://mdster.com/pricing) - [About](https://mdster.com/about) ### Resources - [Blog](https://mdster.com/blog) - [Dashboard](https://mdster.com/user/dashboard) ### Support - [Contact](https://mdster.com/contact) - [Legal & Policies](https://mdster.com/legal) - [Medical Reviewers](https://mdster.com/medical-reviewers) © 2026 MDster [ ](https://play.google.com/store/apps/details?id=com.mdster.app) [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy) reCAPTCHA Protected by reCAPTCHA. Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply. Cookie Consent -------------- We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) & [ Privacy Policy ](https://mdster.com/privacy) Accept